Clinical Trial Results: Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and effectiveness of slowly increasing dose and food effect of KarXT in participants with schizophrenia; study completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• KarXT (xanomeline-trospium)

Snippet

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2026-06-22